These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Chandrasekar T; Yang JC; Gao AC; Evans CP Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148 [TBL] [Abstract][Full Text] [Related]
3. New and emerging agents for the treatment of castration-resistant prostate cancer. Higano CS; Crawford ED Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
6. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Leibowitz-Amit R; Joshua AM Curr Oncol; 2012 Dec; 19(Suppl 3):S22-31. PubMed ID: 23355790 [TBL] [Abstract][Full Text] [Related]
7. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Fizazi K; Smith MR; Tombal B Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098 [TBL] [Abstract][Full Text] [Related]
8. Emerging targeted therapies for castration-resistant prostate cancer. Adamo V; Noto L; Franchina T; Chiofalo G; Picciotto M; Toscano G; Caristi N Front Endocrinol (Lausanne); 2012; 3():73. PubMed ID: 22666217 [TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. Ojo D; Lin X; Wong N; Gu Y; Tang D Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949 [TBL] [Abstract][Full Text] [Related]
11. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Schweizer MT; Antonarakis ES Ther Adv Urol; 2012 Aug; 4(4):167-78. PubMed ID: 22852027 [TBL] [Abstract][Full Text] [Related]
12. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. Schalken J; Fitzpatrick JM BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596 [TBL] [Abstract][Full Text] [Related]
13. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. Fujimoto N J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726 [TBL] [Abstract][Full Text] [Related]
14. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Semenas J; Dizeyi N; Persson JL Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414 [TBL] [Abstract][Full Text] [Related]
15. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640 [TBL] [Abstract][Full Text] [Related]
17. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. Dellis A; Papatsoris AG Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621 [TBL] [Abstract][Full Text] [Related]
18. Novel agents in the management of castration resistant prostate cancer. Chaturvedi S; Garcia JA J Carcinog; 2014; 13():5. PubMed ID: 24799832 [TBL] [Abstract][Full Text] [Related]